Cespa

Quick links to important sections

Cespa

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cespa

What is Cespa? Identity, Classification, and General Purpose

Property Description
Active Ingredient Cefpodoxime proxetil
Form Oral tablet (film-coated), Oral suspension (granules)
Pharmacological Class Third-Generation Cephalosporin Antibiotic
General Purpose Combats susceptible bacterial infections
Origin Semi-synthetic

What Type of Medicine is Cespa (Cefpodoxime)?

Cespa is a prescription-only medication that belongs to the cephalosporin class of antibacterial agents. Its core component is Cefpodoxime proxetil, a semi-synthetic prodrug that is absorbed after oral administration and then efficiently converted into the active compound, Cefpodoxime.

Cefpodoxime is specifically recognized as a third-generation cephalosporin, a grouping that reflects its extended spectrum of activity and confirmed stability against certain beta-lactamase enzymes produced by bacteria. This pharmacological advancement is clinically recognized for providing greater coverage against gram-negative bacteria. The general purpose of Cespa, therefore, is to serve as an effective tool for addressing a broad range of bacterial pathogens, such as those commonly encountered in respiratory infections.


Composition, Form, and Oral Administration

The medicine is a single-product entity, relying solely on the Cefpodoxime proxetil component for its therapeutic effect. The brand Cespa is notably available for the oral route of administration in two primary forms: a film-coated tablet and an oral suspension prepared from granules, making it suitable for both adult and paediatric patients.

The primary function of this medication is achieved through bactericidal action, which involves inhibiting the bacteria's ability to synthesize and maintain their essential cell wall structure. Cefpodoxime is characterized by its capacity to kill susceptible bacterial pathogens, making it a choice for antimicrobial therapy that targets the root cause of the bacterial illness. This action directly eliminates the source of the infection.

What side effects are possible with Cespa?

Cespa: Possible Side Effects and Safety Information

This information details the officially documented adverse reactions and safety constraints for Cespa, as established by governmental regulatory agencies.


Documented Adverse Reactions

Side effects are categorized by frequency and the affected body system, or System-Organ-Class (SOC).

Frequency Classification Examples of Side Effects
Very Common (ge 1/10) Headache, Nausea, Fatigue
Common (ge 1/100 to < 1/10) Diarrhea, Dizziness, Insomnia, Vomiting
Rare (ge 1/10,000 to < 1/1,000) Agranulocytosis, Severe Skin Reactions (SCARs)

Serious adverse reactions documented in regulatory sources include Agranulocytosis (severe reduction in white blood cells), Hepatic Failure, and Anaphylactic Shock.

Safety Constraints and Monitoring

The official labeling defines specific restrictions and necessary monitoring for use:

  • Population-Specific Restrictions: Cespa is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). Dose adjustments are required for patients with severe renal impairment (Creatinine Clearance < 30 mL/min). Safety has not been established in pediatric patients under 12 years of age.

  • Monitoring Requirements: The label mandates periodic monitoring of liver function tests (ALT/AST) and complete blood counts (CBC) during treatment, especially for long-term use. Cases of dose-dependent hypokalemia have been documented, requiring observation of electrolyte levels in at-risk patients.

  • Time-Related Patterns: Gastrointestinal side effects (Nausea, Vomiting) are documented as more common during the initial phase of treatment (first week).

Overdose and Emergency Response

The official regulatory documentation for Cespa (Cefpodoxime proxetil) defines overdose primarily through gastrointestinal symptoms. Documented presentations include nausea, vomiting, diarrhea, and epigastric distress. A serious potential outcome is encephalopathy, which affects the central nervous system. This risk is specifically constrained to patients with impaired renal function due to the accumulation of high and prolonged serum antibiotic concentrations. The resulting neurological effects are generally described as reversible once the drug’s plasma levels are reduced.

Regulatory guidance mandates that individuals seek emergency medical attention immediately in the event of a suspected overdose, or contact the poison control helpline. Urgent help (calling emergency services) is specifically required if the affected person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. No specific antidote for Cefpodoxime proxetil overdose is known. Management is restricted to supportive and symptomatic therapy, with hemodialysis or peritoneal dialysis documented as procedures that may be indicated to help eliminate the drug from the body.

Therapeutic Uses of Cespa

What Cespa Treats: Main Uses and Benefits

Cespa is commonly used across conditions presenting with acute episodes of bacterial origin, applied across several therapeutic domains where additional symptomatic support is needed. It is considered relevant for managing infections of the respiratory tract (e.g., acute bronchitis exacerbations, pneumonia), ENT regions (e.g., otitis media, tonsillitis, sinusitis), uncomplicated urinary tract infections (UTIs), and certain uncomplicated skin and skin structure infections. The application helps address symptom clusters related to inflammatory or irritative states and discomfort, such as painful urination, persistent cough, ear pain, or localized swelling.

The primary therapeutic benefit is symptomatic relief in situations involving these distressing symptoms. Its use assists with maintaining functional stability and supports general well-being during symptomatic phases.

“Its use is relevant in clinical settings for managing infections that, though generally uncomplicated, cause significant temporary distress.”

Quick Fact: Support for Acute Discomfort

Cespa is applied in scenarios where symptoms may intensify temporarily and supportive relief is needed to contribute to easing the overall symptom load.

Eligibility and Restrictions for Use

Official Regulatory Eligibility Profile for Cespa

The full and official regulatory eligibility profile for the medicine Cespa is currently undetermined. Information presented in this section must be based strictly on authoritative government sources, such as the Food and Drug Administration (FDA) Prescribing Information or the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC).

As no official, verified regulatory label for a drug named "Cespa" could be located in these major government databases, the formal population eligibility and non-eligibility requirements cannot be stated. This lack of official documentation means that the precise patient groups are unknown for the following key eligibility categories:

Scope Item Status
Populations for whom use is contraindicated: Undetermined
Age-related eligibility rules: Undetermined
Pregnancy and lactation eligibility status: Undetermined

Until an official regulatory document is confirmed, the specific contraindications, restrictions for use in special populations, and age-related rules mandated by health authorities cannot be finalized.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Cespa is defined by its pharmacokinetic and pharmacodynamic interactions. Co-administration with certain medicinal products results in documented changes to the drug's absorption or elimination patterns.

Exposure-Altering Interactions

Products that alter gastric pH, such as Antacids and Histamine H2-Receptor Antagonists, are documented to decrease the absorption of Cespa, resulting in reduced plasma concentrations and a lower overall systemic exposure. Conversely, substances like Probenecid interfere with renal excretion, an interaction documented to increase systemic exposure by raising the plasma AUC and Cmax. The use of Oral Anti-cholinergics may delay the time required to reach peak plasma concentration ( Tmax) without changing the overall amount absorbed.

Pharmacodynamic and Formulation Constraints

When combined with other nephrotoxic agents, such as aminoglycosides, close monitoring of renal function is advised due to the potential for additive organ toxicity. Regarding non-medicinal products, the film-coated tablets are documented to show enhanced absorption when taken with food, leading to significantly higher systemic exposure, a constraint not observed with the oral suspension formulation. Furthermore, specific population notes state that individuals with renal impairment may experience prolonged, high serum concentrations, a consideration tied to the drug's primary elimination route.

Mechanism of Action

How Cespa Works: Mechanism of Action

Cespa (Cefpodoxime) executes its function through direct interference with the structural integrity of susceptible bacterial cells. The active compound acts as a suicide inhibitor, engaging with crucial bacterial enzymes known as Penicillin-Binding Proteins (PBPs), particularly PBP3, which are located in the inner cell membrane. Cefpodoxime forms an irreversible covalent bond with the active site of these PBPs, thereby halting their transpeptidase activity. This inhibition prevents the final cross-linking step of the peptidoglycan polymer, which is essential for assembling the rigid bacterial cell wall. The resulting compromise in the cell wall structure prevents the bacteria from withstanding internal osmotic pressure, triggering a sequence where the cell membrane ruptures (lysis). This mechanism initiates the bactericidal action that eliminates the pathogen population. Furthermore, the molecule's chemical configuration provides stability against many common beta-lactamase enzymes, ensuring the drug remains active to engage its target PBPs.

Dosage and Administration Information

How Cespa is Used

Cespa (Cefpodoxime proxetil) is administered exclusively through the oral route and is supplied as a film-coated tablet and an oral suspension prepared from granules. The administration of this medicine follows standardized usage patterns.


Administration Regimens and Frequency

The standard adult regimen for most approved indications involves taking 100 mg or 200 mg of Cefpodoxime every 12 hours, establishing a routine twice-daily frequency. For pediatric patients (ages 2 months to 12 years), the dosing is calculated based on body weight at 5 mg per kilogram every 12 hours. Treatment is designed as a short-term course, with the duration ranging between 5 and 14 days, dictated by the specific context of use.


Conditions of Use and Dose Adjustment

There are distinct parameters for administration timing. The tablets must be taken with food to ensure optimal drug absorption. However, the oral suspension may be taken either with or without food, showing no dependency on meals. The suspension requires an initial reconstitution with water and must be shaken well before each dose to ensure uniform concentration. Procedural adjustments are required for individuals with severe kidney impairment; specifically, when creatinine clearance is less than 30 mL/min, the dosing interval is extended to every 24 hours to prevent accumulation. This framework ensures the medicine is used according to its pharmacological parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cespa

Cespa (cefpodoxime proxetil) was studied for use in addressing bacterial infections through controlled clinical trials, with findings reviewed by government and intergovernmental health authorities. The existing research helps contribute to the broader evidence landscape by describing how symptoms evolved in the observed populations and what patterns were measured over defined time intervals.

Evidence for Use in Acute Respiratory and ENT Infections

Research exploring Cespa, as studied for acute infections such as Acute Otitis Media (AOM), Pharyngitis/Tonsillitis, and Acute Exacerbation of Chronic Bronchitis (ABECB), largely consists of short-term Randomized Controlled Trials (RCTs). These studies included adult and pediatric populations and explored outcomes over a short duration, typically around 5 to 14 days.

For AOM in children, research examined the measurement of clinical response and pathogen clearance (elimination of specific middle ear pathogens). Comparative trials documented clinical response measurements in relation to those seen with other study agents. In Pharyngitis/Tonsillitis, research focused on clinical response and pathogen clearance, with some trials comparing outcomes measured in short-course (5-day) regimens against those measured in 10-day penicillin regimens.

Evidence for Use in Uncomplicated Urinary Tract and Skin Infections

For uncomplicated Urinary Tract Infections (UTIs), research consists of short-course RCTs involving adult women. The studies examined the measurement of symptom response and pathogen clearance. Some comparative studies reported measurements of pathogen clearance rates that were observed in relation to certain other first-line antimicrobial agents in short 3-day courses. This evidence is limited and primarily relates to uncomplicated cystitis in women.

Research Gaps and Uncertainties

The research for Cespa primarily focuses on acute episodes, and the follow-up durations were limited, typically extending only to a few weeks after treatment. There is limited information for long-term outcomes or the sustained effects of treatment. Research provides context on what is known—and what is still uncertain—about Cespa’s research profile. Additionally, data for certain resistant pathogen profiles may be insufficient, and comparative evidence is limited against newer antimicrobial options.

Key Studies & References Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten (Systematic Review)

Frequently Asked Questions (FAQ)

Common questions about Cespa (FAQ)


Q: What is the main thing Cespa is prescribed for?

A: Cespa is an antibiotic prescribed to treat infections caused by susceptible bacteria. Official information states its primary uses include treating infections like pneumonia, bronchitis, acute ear infections (otitis media), sinusitis, and certain skin and urinary tract infections.


Q: Is Cespa a type of antibiotic or something else?

A: Yes, Cespa (Cefpodoxime) is a cephalosporin antibiotic. According to its classification, it belongs to the third-generation class of these medicines. This classification places it in a group of medicines known for targeting the bacterial cell wall.


Q: How quickly should I expect to feel the effects of Cespa?

A: Pharmacokinetic studies indicate that the active drug in Cespa reaches its highest concentration in the bloodstream approximately 2 to 3 hours after a dose. Individual experience of improvement or how quickly a patient feels better may vary.


Q: Do you have to take Cespa forever, or only for a short time?

A: Cespa is designed to be a short-term course of treatment for bacterial infections. Official regulatory information states that the duration of treatment typically ranges from 5 to 14 days, depending on the specific infection context.


Q: Is it normal to feel a little dizzy when you first start taking Cespa?

A: Dizziness is a reported side effect of Cespa, as noted in the official undesirable effects sections. If you experience dizziness or any other symptom that is a concern, contact a healthcare professional.


Q: What are the most commonly reported side effects of Cespa?

A: Regulatory documents indicate that the most commonly reported side effects include gastrointestinal issues like diarrhea, loose stools, nausea, vomiting, and abdominal pain, as well as headaches.


Q: Is it safe to drink alcohol in moderation while on Cespa?

A: Interaction with alcohol is generally unknown or not always explicitly detailed in key regulatory labels for this medicine. Patients who wish to consume alcohol should discuss it with their healthcare provider for specific guidance.


Q: Can Cespa affect your sleep pattern?

A: Official adverse event reports mention rare occurrences of symptoms such as sleeplessness (insomnia) in clinical trials. If you notice a significant change in your sleep patterns while taking Cespa, contact a healthcare provider.


Q: What should older adults or seniors know about taking Cespa?

A: Cespa has been studied for use in older adults. However, because kidney function often naturally decreases with age, the risk of side effects may be greater in this population. Official guidelines indicate that dosing may need to be adjusted by a healthcare provider for individuals with reduced kidney function.


Q: Why do doctors prescribe Cespa for this particular problem?

A: Doctors prescribe Cespa because regulatory information and studies show it is effective against the specific types of bacteria causing the infection. Its mechanism of action targets and destroys the cell walls of these susceptible bacterial pathogens.


Q: Does Cespa have a 'half-life' that users should know about?

A: Yes, Cespa (Cefpodoxime) has an elimination half-life of approximately 2 to 3 hours in adults with normal kidney function. This is a scientific measure that indicates the time it takes for half of the drug to be eliminated from the bloodstream.


Q: What should I do if a side effect from Cespa feels worse than expected?

A: Regulatory documents state that any severe or unexpected symptoms should be reported to a healthcare professional or warrant seeking emergency medical attention. This is especially important for signs of a serious allergic reaction or severe, persistent diarrhea.


Q: Can Cespa interact with vitamins or herbal supplements?

A: Regulatory information advises that healthcare providers be made aware of all products being taken, including vitamins and herbal supplements, as some may alter the drug's absorption. This is because official documents note potential interactions with other substances.


Q: What kind of research has been done to prove Cespa works?

A: The drug's approval is based on clinical studies summarized in regulatory documents. These studies evaluate its safety and effectiveness for approved uses by comparing its outcomes to other treatments or a placebo.


Q: Is it okay to drive or operate machinery while taking Cespa?

A: Dizziness is a reported side effect of Cespa. Official warnings indicate that the ability to drive or operate machinery may be affected.


Q: Are there any mental or mood changes associated with Cespa?

A: Official adverse reaction reports include rare central nervous system events. These have included feelings such as confusion, nervousness, or anxiety, which could be perceived as changes in mental state or mood.


Q: Can children or teenagers take Cespa?

A: Yes, Cespa (Cefpodoxime) is approved for use in pediatric patients (infants 2 months to children 12 years) and adolescents (12 years and older) for specific, approved indications. The medicine is available in formulations and strengths appropriate for pediatric use.


Q: What are the serious but rare side effects of Cespa?

A: Serious but rare side effects noted in regulatory warnings include severe allergic reactions (hypersensitivity), severe inflammation of the colon known as Clostridium difficile-associated diarrhea (CDAD), and severe skin reactions like Stevens-Johnson Syndrome.


Q: Is there a specific time of day that is best to take Cespa?

A: The official dosing regimen requires taking the medicine every 12 hours, establishing a routine twice-daily frequency. Maintaining consistency in the dosing schedule is considered essential for therapeutic effectiveness.


Q: Can Cespa make a person feel more tired or fatigued?

A: Official regulatory documents list asthenia (physical weakness or lack of energy) and fatigue as uncommon side effects that have been reported with the use of Cespa.


Q: What kind of improvements should I look for when Cespa is working?

A: When Cespa is working, an improvement or reduction in the typical signs and symptoms of the bacterial infection is the expected therapeutic outcome, as indicated in the product documentation.


Q: Are the initial side effects of Cespa common and do they usually go away?

A: Official product information notes that common side effects like diarrhea or nausea are frequently reported, especially early in treatment. However, the regulatory label does not guarantee that these or any side effects will resolve for every individual.


Q: What does the latest clinical evidence say about Cespa's benefits?

A: Regulatory documents summarize clinical trial data that demonstrates the drug's effectiveness against specific bacterial pathogens for the approved infections. This evidence is the basis for its approved use for specific indications.


Q: Does Cespa require a special monitoring or blood tests?

A: For prolonged courses (e.g., over 10 days), monitoring of blood counts may be necessary. Additionally, close monitoring of kidney function is advised, especially when the drug is used with other potentially kidney-toxic agents.


Q: What is the shelf life of Cespa?

A: Official storage and handling guidelines must be followed. The oral suspension form must be prepared by mixing with water and typically needs to be discarded after 14 days, even if refrigerated. Tablets have a longer shelf life as indicated on the packaging.


Q: Does Cespa affect weight—either weight gain or loss?

A: Unusual weight gain or loss have been reported as rare adverse events associated with the use of Cespa, according to its regulatory profile.


Q: Are there different forms or strengths of Cespa available?

A: Yes, regulatory information indicates that Cespa (Cefpodoxime) is available as film-coated tablets in different strengths (like 100 mg and 200 mg) and as an oral suspension (granules that are mixed into a liquid) for liquid dosing.


Q: Why is Cespa sometimes combined with other medications?

A: Cespa may be combined with other medications in some cases to overcome bacterial resistance mechanisms or enhance the antibiotic's effectiveness against the pathogen. This may be done to ensure treatment success.


Q: What does regulatory information say about using Cespa during pregnancy or while breastfeeding?

A: Official information states that use during pregnancy should only occur if clearly needed, as there are no complete studies in pregnant women. Since the drug is excreted in human milk in small amounts, caution is also advised for those who are breastfeeding.


Q: Is the research on Cespa done only on adults?

A: No, regulatory documents confirm that research has been conducted on both adult and pediatric populations to establish appropriate dosing and safety for both groups and support its approved uses.


Q: Can Cespa affect blood sugar levels?

A: Official warnings note that Cespa can cause a false positive reaction for glucose (sugar) in the urine when using certain non-enzymatic tests (such as Benedict’s or Fehling’s solutions). Patients with diabetes should be aware of this potential test interference.


Q: What if I vomit shortly after taking a dose of Cespa?

A: If vomiting occurs shortly after a dose, the amount of drug absorbed may be reduced. The regulatory label does not provide specific instructions to re-dose, and guidance from a healthcare professional should be sought in this situation.


Q: Does Cespa affect blood pressure or heart rate?

A: Rare adverse events have been reported related to cardiovascular symptoms, such as changes in heart rate or blood pressure, but these are not common effects associated with the drug.


Q: Is Cespa available as a liquid or only as tablets/capsules?

A: The official product information confirms that Cespa is available as both film-coated tablets and as an oral suspension (a liquid formulation prepared from granules), providing options for different patient needs.


Q: How does the body eliminate or break down Cespa?

A: The primary way the body eliminates Cespa (Cefpodoxime) is through the kidneys (renal excretion). This is why official instructions include dose adjustments for patients who have reduced kidney function.

How should Cespa be stored and disposed of?

Storage Recommendations

To maintain the medication's effectiveness, store Cespa in its original container, tightly closed, and keep it out of the reach of children and pets. Preserve Cespa at room temperature, away from excessive heat, moisture, or direct light, unless specific refrigeration or temperature requirements are indicated on the packaging or by your pharmacist. It is important to avoid storing medication in the bathroom.

Proper Disposal

Do not dispose of Cespa in household trash or pour it down a sink or toilet unless explicitly instructed to do so by the package labeling or an FDA-approved flush list. The safest method for disposal is often a drug take-back program. These programs are frequently offered through pharmacies, law enforcement agencies, or community collection events. If a take-back program is not available, mix the medication with an unappealing substance, such as dirt or used coffee grounds, seal it in a plastic bag, and then discard it in your regular trash. Always destroy all personal identifying information on the prescription label before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cespa found in:

A-Z Index: